Viridiana Arreola
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Viridiana Arreola has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Pere Clavé
Gastrointestinal Physiology Laboratory, Department of Surgery, CIBERehd CSdM-UAB, Hospital Universitari de Mataró, Consorci Sanitari del Maresme, Universitat Autònoma de Barcelona, Carretera de Cirera 230, 08304, Mataró (Barcelona), Spain.
3 shared publications - Weslania Viviane Nascimento
Gastrointestinal Physiology Laboratory, Hospital de Mataró, Universitat Autónoma de Barcelona, Mataró, Spain
3 shared publications - Alberto Martin
Gastrointestinal Physiology Laboratory, Department of Surgery, Hospital Universitari de Mataró, Consorci Sanitari del Maresme, Universitat Autònoma de Barcelona, C. Cirera s/n, Barcelona, 08304, Spain, 34 937417700
2 shared publications - Laia Rofes
Gastrointestinal Physiology Laboratory, Department of Surgery, Hospital de Mataró, Universitat Autònoma de Barcelona, Mataró, Spain
2 shared publications - Mireia Bolivar-Prados
Gastrointestinal Physiology Laboratory, Hospital de Mataró, Universitat Autònoma de Barcelona, 08304 Mataró, Spain
2 shared publications - Omar Ortega
Gastrointestinal Physiology Laboratory, Department of Surgery, Hospital Universitari de Mataró, Consorci Sanitari del Maresme, Universitat Autònoma de Barcelona, C. Cirera s/n, Barcelona, 08304, Spain, 34 937417700
2 shared publications
Latest Publications
- Open Access
- 1 December 2022
- Published by Elsevier in Clinical Nutrition
- Vol. 41 (12) , 2996-3006
COVID-19 is associated with oropharyngeal dysphagia and malnutrition in hospitalized patients during the spring 2020 wave of the pandemic
- 1 December 2022
- Published by Elsevier in Clinical Nutrition
- Vol. 41 (12) , 2996-3006
Open AccessCOVID-19 is associated with oropharyngeal dysphagia and malnutrition in hospitalized patients during the spring 2020 wave of the pandemic
- Open Access
- 16 February 2020
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 32 (6) , e13821
A randomized clinical trial on the acute therapeutic effect of TRPA1 and TRPM8 agonists in patients with oropharyngeal dysphagia
Background: Oropharyngeal dysphagia (OD) treatment is moving away from compensatory strategies toward active treatments that improve swallowing function. The aim of this study was to assess the acute therapeutic effect of TRPA1/M8 agonists in improving swallowing function in OD patients.Methods: Fifty‐eight patients with OD caused by aging, stroke, or neurodegenerative disease were included in a three‐arm, quadruple‐blind, randomized clinical trial (NCT02193438). Swallowing safety and efficacy and the kinematics of the swallow response were assessed by videofluoroscopy (VFS) during the swallow of 182 ± 2 mPa·s viscosity (nectar) boluses of a xanthan gum thickener supplemented with (a) 756.6 μmol/L cinnamaldehyde and 70 μmol/L zinc (CIN‐Zn) (TRPA1 agonists), (b) 1.6 mmol/L citral (CIT) (TRPA1 agonist), or (c) 1.6 mmol/L citral and 1.3 mmol/L isopulegol (CIT‐ISO) (TRPA1 and TRPM8 agonists). The effects on pharyngeal event‐related potentials (ERP) were assessed by electroencephalography.Key Results: TRPA1 stimulation with either CIN‐Zn or CIT reduced time to laryngeal vestibule closure (CIN‐Zn P = .002, CIT P = .023) and upper esophageal sphincter opening (CIN‐Zn P = .007, CIT P = .035). In addition, CIN‐Zn reduced the penetration‐aspiration scale score (P = .009), increased the prevalence of safe swallows (P = .041), and reduced the latency of the P2 peak of the ERP. CIT‐ISO had no positive effect on biomechanics or neurophysiology. No significant adverse events were observed.Conclusions and Inferences: TRPA1 stimulation with CIN‐Zn or CIT improves the swallow response which, in the case of CIN‐Zn, is associated with a significant improvement in cortical activation and safety of swallow. These results provide the basis for the development of new active treatments for OD using TRPA1 agonists.
- 16 February 2020
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 32 (6) , e13821
Open AccessA randomized clinical trial on the acute therapeutic effect of TRPA1 and TRPM8 agonists in patients with oropharyngeal dysphagia
Background: Oropharyngeal dysphagia (OD) treatment is moving away from compensatory strategies toward active treatments that improve swallowing function. The aim of this study was to assess the acute therapeutic effect of TRPA1/M8 agonists in improving swallowing function in OD patients.Methods: Fifty‐eight patients with OD caused by aging, stroke, or neurodegenerative disease were included in a three‐arm, quadruple‐blind, randomized clinical trial (NCT02193438). Swallowing safety and efficacy and the kinematics of the swallow response were assessed by videofluoroscopy (VFS) during the swallow of 182 ± 2 mPa·s viscosity (nectar) boluses of a xanthan gum thickener supplemented with (a) 756.6 μmol/L cinnamaldehyde and 70 μmol/L zinc (CIN‐Zn) (TRPA1 agonists), (b) 1.6 mmol/L citral (CIT) (TRPA1 agonist), or (c) 1.6 mmol/L citral and 1.3 mmol/L isopulegol (CIT‐ISO) (TRPA1 and TRPM8 agonists). The effects on pharyngeal event‐related potentials (ERP) were assessed by electroencephalography.Key Results: TRPA1 stimulation with either CIN‐Zn or CIT reduced time to laryngeal vestibule closure (CIN‐Zn P = .002, CIT P = .023) and upper esophageal sphincter opening (CIN‐Zn P = .007, CIT P = .035). In addition, CIN‐Zn reduced the penetration‐aspiration scale score (P = .009), increased the prevalence of safe swallows (P = .041), and reduced the latency of the P2 peak of the ERP. CIT‐ISO had no positive effect on biomechanics or neurophysiology. No significant adverse events were observed.Conclusions and Inferences: TRPA1 stimulation with CIN‐Zn or CIT improves the swallow response which, in the case of CIN‐Zn, is associated with a significant improvement in cortical activation and safety of swallow. These results provide the basis for the development of new active treatments for OD using TRPA1 agonists.
- Open Access
- 11 August 2019
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 31 (11) , e13695
Effect of a gum‐based thickener on the safety of swallowing in patients with poststroke oropharyngeal dysphagia
Background: Increasing viscosity with thickening agents is a valid therapeutic strategy for oropharyngeal dysphagia (OD). To assess the therapeutic effect of a xanthan gum‐based thickener (Nutilis Clear®) at six viscosities compared with thin liquid in poststroke OD (PSOD) patients.Methods: A total of 120 patients with PSOD were studied in this controlled, multiple‐dose, fixed‐order, and single‐blind study using videofluoroscopy (VFSS). A series of boluses of 10 mL thin liquid and 2000, 1400, 800, 450, 250, and 150 mPa s viscosities were given in duplicate, interrupted in case of aspiration. We assessed the safety and efficacy of swallow and the kinematics of the swallow response.Key Results: A total of 41.2% patients had safe swallow at thin liquid which significantly increased for all viscosities from 71.9% at 150 mPa s to 95.6% at 1400 mPa s (P < .001). PAS score (3.7 ± 2.3) at thin liquid was also reduced by increasing bolus viscosity (P < .001). The prevalence of patients with aspiration at thin liquid was 17.5% and decreased at all viscosities (P < .01), except at 150 mPa s. Increasing viscosity shortened time to laryngeal vestibule closure (LVC) at all viscosities (P < .01) and reduced bolus velocity at ≥450 mPa s (P < .05). The prevalence of patients with pharyngeal residue at each viscosity 37.7%‐44.7% was similar to that at thin liquid (41.2%).Conclusions and Inferences: The prevalence of unsafe swallow with thin liquids is very high in PSOD. Increasing shear bolus viscosity with this xanthan gum‐based thickener significantly increased the safety of swallow in patients with PSOD in a viscosity‐dependent manner without increasing the prevalence of pharyngeal residue.
- 11 August 2019
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 31 (11) , e13695
Open AccessEffect of a gum‐based thickener on the safety of swallowing in patients with poststroke oropharyngeal dysphagia
Background: Increasing viscosity with thickening agents is a valid therapeutic strategy for oropharyngeal dysphagia (OD). To assess the therapeutic effect of a xanthan gum‐based thickener (Nutilis Clear®) at six viscosities compared with thin liquid in poststroke OD (PSOD) patients.Methods: A total of 120 patients with PSOD were studied in this controlled, multiple‐dose, fixed‐order, and single‐blind study using videofluoroscopy (VFSS). A series of boluses of 10 mL thin liquid and 2000, 1400, 800, 450, 250, and 150 mPa s viscosities were given in duplicate, interrupted in case of aspiration. We assessed the safety and efficacy of swallow and the kinematics of the swallow response.Key Results: A total of 41.2% patients had safe swallow at thin liquid which significantly increased for all viscosities from 71.9% at 150 mPa s to 95.6% at 1400 mPa s (P < .001). PAS score (3.7 ± 2.3) at thin liquid was also reduced by increasing bolus viscosity (P < .001). The prevalence of patients with aspiration at thin liquid was 17.5% and decreased at all viscosities (P < .01), except at 150 mPa s. Increasing viscosity shortened time to laryngeal vestibule closure (LVC) at all viscosities (P < .01) and reduced bolus velocity at ≥450 mPa s (P < .05). The prevalence of patients with pharyngeal residue at each viscosity 37.7%‐44.7% was similar to that at thin liquid (41.2%).Conclusions and Inferences: The prevalence of unsafe swallow with thin liquids is very high in PSOD. Increasing shear bolus viscosity with this xanthan gum‐based thickener significantly increased the safety of swallow in patients with PSOD in a viscosity‐dependent manner without increasing the prevalence of pharyngeal residue.